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Abstract 
Background: Worldwide, more than 100 million women between the ages of 15 and 49 years take oral 
contraceptive pills (OCPs). OCP use increases the risk of venous thromboembolism (VTE) through its 
primary drug, ethinylestradiol, which slows liver metabolism, promotes tissue retention, and ultimately 
favors fibrinolysis inhibition and thrombosis. 
Purpose: To evaluate the effects of OCP use on VTE after arthroscopic shoulder surgery. 
Study Design: Cohort study; Level of evidence, 3. 
Methods: A large national payer database (PearlDiver) was queried for patients undergoing arthroscopic 
shoulder surgery. The incidence of VTE was evaluated in female patients taking OCPs and those not 
taking OCPs. A matched group was subsequently created to evaluate the incidence of VTE in similar 
patients with and without OCP use. 
Results: A total of 57,727 patients underwent arthroscopic shoulder surgery from 2007 to 2016, and 
26,365 patients (45.7%) were female. At the time of surgery, 924 female patients (3.5%) were taking 
OCPs. The incidence of vascular thrombosis was 0.57% (n = 328) after arthroscopic shoulder surgery, and 
there was no significant difference in the rate of vascular thrombosis in male or female patients (0.57% vs 
0.57%, respectively; P > .99). The incidence of VTE in female patients taking and not taking OCPs was 
0.22% and 0.57%, respectively (P = .2). In a matched-group analysis, no significant difference existed in 
VTE incidence between patients with versus without OCP use (0.22% vs 0.56%, respectively; P = .2). On 
multivariate analysis, hypertension (odds ratio [OR], 2.00; P < .001) and obesity (OR, 1.43; P = .002) were 
risk factors for VTE. 
Conclusion: OCP use at the time of arthroscopic shoulder surgery is not associated with an increased risk 
of VTE. Obesity and hypertension are associated with a greater risk for thrombolic events, although the 
risk remains very low. Our findings suggest that patients taking OCPs should be managed according to 
the surgeon’s standard prophylaxis protocol for arthroscopic shoulder surgery. 
Keywords 
oral contraceptives, shoulder arthroscopic surgery, deep vein thrombosis, complications 
Disciplines 
Orthopedics | Sports Sciences 
Notes/Citation Information 
Published in Orthopaedic Journal of Sports Medicine, v. 7, issue 1, p. 1-5. 
© The Author(s) 2019 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
4.0 License (http://www.creativecommons.org/licenses/by-nc-nd/4.0/) which permits non-commercial 
use, reproduction and distribution of the work as published without adaptation or alteration, without 
further permission provided the original work is attributed as specified on the SAGE and Open Access 
pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). 
Authors 
Austin V. Stone, Avinesh Agarwalla, Anirudh K. Gowd, Cale A. Jacobs, Jeffrey A Macalena, Bryson P. 
Lesniak, Nikhil N. Verma, Anthony A. Romeo, and Brian Forsythe 
This article is available at UKnowledge: https://uknowledge.uky.edu/orthopaedicsurgery_facpub/21 
Original Research
Oral Contraceptive Pills Are Not
a Risk Factor for Deep Vein Thrombosis
or Pulmonary Embolism After
Arthroscopic Shoulder Surgery
Austin V. Stone,* MD, PhD, Avinesh Agarwalla,† BS, Anirudh K. Gowd,† BS, Cale A. Jacobs,* PhD,
Jeffrey A. Macalena,‡ MD, Bryson P. Lesniak,§ MD, Nikhil N. Verma,† MD,
Anthony A. Romeo,|| MD, and Brian Forsythe,†{ MD
Investigation performed at Midwest Orthopaedics at Rush,
Rush University Medical Center, Chicago, Illinois, USA
Background:Worldwide, more than 100 million women between the ages of 15 and 49 years take oral contraceptive pills (OCPs).
OCP use increases the risk of venous thromboembolism (VTE) through its primary drug, ethinylestradiol, which slows liver
metabolism, promotes tissue retention, and ultimately favors fibrinolysis inhibition and thrombosis.
Purpose: To evaluate the effects of OCP use on VTE after arthroscopic shoulder surgery.
Study Design: Cohort study; Level of evidence, 3.
Methods: A large national payer database (PearlDiver) was queried for patients undergoing arthroscopic shoulder surgery. The
incidence of VTE was evaluated in female patients taking OCPs and those not taking OCPs. A matched group was subsequently
created to evaluate the incidence of VTE in similar patients with and without OCP use.
Results: A total of 57,727 patients underwent arthroscopic shoulder surgery from 2007 to 2016, and 26,365 patients (45.7%) were
female. At the time of surgery, 924 female patients (3.5%) were taking OCPs. The incidence of vascular thrombosis was 0.57%
(n ¼ 328) after arthroscopic shoulder surgery, and there was no significant difference in the rate of vascular thrombosis in male or
female patients (0.57% vs 0.57%, respectively; P > .99). The incidence of VTE in female patients taking and not taking OCPs was
0.22% and 0.57%, respectively (P ¼ .2). In a matched-group analysis, no significant difference existed in VTE incidence between
patients with versus without OCP use (0.22% vs 0.56%, respectively; P ¼ .2). On multivariate analysis, hypertension (odds ratio
[OR], 2.00; P < .001) and obesity (OR, 1.43; P ¼ .002) were risk factors for VTE.
Conclusion: OCP use at the time of arthroscopic shoulder surgery is not associated with an increased risk of VTE. Obesity and
hypertension are associated with a greater risk for thrombolic events, although the risk remains very low. Our findings suggest that
patients taking OCPs should be managed according to the surgeon’s standard prophylaxis protocol for arthroscopic shoulder
surgery.
Keywords: oral contraceptives; shoulder arthroscopic surgery; deep vein thrombosis; complications
Arthroscopic shoulder surgery is one of the most frequently
performed orthopaedic procedures.12 The procedure is gen-
erally considered to have a low risk for complications in
general and particularly with regard to the development
of vascular thrombosis.4,6,10,20,22,25 While vascular throm-
bosis is the leading cause of morbidity and mortality after
joint reconstruction,1,21 there is significantly less informa-
tion regarding the risk factors and implementation of pre-
ventive measures for venous thromboembolism (VTE; deep
vein thrombosis [DVT] and/or pulmonary embolism [PE])
after arthroscopic shoulder surgery. The rate of VTE after
arthroscopic shoulder surgery has been shown to range
from 0.01% to 0.31%, while the rate of asymptomatic VTE
is as high as 5.7%.3,6,10,11,15,20
Although symptomatic thromboembolic events are rare
after shoulder surgery, these complications are attributed
to 20% of hospital admissions within 30 days of arthroscopic
shoulder surgery.9 Because of the effect of readmissions on
the health care system, it is imperative to identify risk fac-
tors that may contribute to postoperative adverse
events.9,16,19,22 History of cancer, blood disorders, history
of tobacco use, operative time, and lateral positioning have
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been identified as potential risk factors for venous throm-
bosis after arthroscopic shoulder surgery.2,4,8,13 A limited
number of studies have investigated risk factors for the
development of VTE after shoulder surgery, and to date,
no study has investigated the use of oral contraceptive pills
(OCPs) at the time of arthroscopic shoulder surgery.5,20
Worldwide, more than 100 million women between the
ages of 15 and 49 years take OCPs.17 OCP use increases the
risk of VTE through its primary drug, ethinylestradiol,
which slows liver metabolism, promotes tissue retention,
and ultimately favors fibrinolysis inhibition and thrombo-
sis.17,23,24 The associated risk of OCP use and thrombolic
events after orthopaedic procedures is unclear. With a large
number of female patients undergoing arthroscopic shoul-
der surgery who may be on OCPs or hormone replacement
therapy, it is of clinical importance to determine the impact
of OCPs on thromboembolic complications.
The purpose of this investigation was to evaluate the
relationship between OCPs and the rate of thromboembolic
complications, including upper and lower extremity DVT
and PE, after arthroscopic shoulder surgery utilizing a
national insurer database. We hypothesized that patients
taking OCPs at the time of surgery would be at a greater
risk of developing postoperative vascular complications in
comparison with patients not taking OCPs at the time of
surgery.
METHODS
The PearlDiver patient records database was queried for
Humana-insured patients from 2007 to 2016. This database
contains deidentified information on more than 20 million
patients in the United States. Patient demographics, hos-
pitalization, diagnoses, procedures, and reimbursement are
accessible from the database. All data can be accessed with
International Classification of Diseases, 9th and 10th Revi-
sions, Clinical Modification (ICD-9-CM and ICD-10-CM,
respectively) procedural codes and Current Procedural Ter-
minology (CPT) codes. The accessed data represent
procedures and diagnoses that were billed to the insurance
company by the provider. PearlDiver documents prescrip-
tion records based on the drug categorization, form,
strength, and/or route of administration. Patients with a
prescription record of OCPs at the time of surgery as iden-
tified by National Drug Codes were queried.
Patients who underwent isolated arthroscopic labral
repair (CPT 29806), superior labral tear from anterior to
posterior (SLAP) repair (CPT 29807), rotator cuff repair
(CPT 29827), or glenohumeral debridement (CPT 29822
or 29823) were identified. Patients who underwent concom-
itant subacromial decompression, distal clavicle excision,
debridement, or biceps tenodesis were included in the
investigation, and those who underwent lysis of adhesions,
manipulation under anesthesia, total shoulder arthro-
plasty, or open rotator cuff repair were excluded from the
study population. Patients with a history of DVT or PE
before the index procedure were identified via ICD-9 and
ICD-10 diagnosis codes. These patients were also excluded,
as a history of VTE is a well-established risk factor.14
Patients who were previously diagnosed with a primary
(ICD-9 289.81) or secondary (ICD-9 289.82) hypercoagula-
ble state or unspecific coagulation disorder (ICD-9 286.9)
were also excluded from this study. Additionally, patients
who underwent subsequent contralateral or ipsilateral
arthroscopic shoulder surgery were counted only once with
their index procedure.
Before matching, multivariate regression was performed
to identify independent risk factors for developing vascular
thrombosis in female patients who underwent arthroscopic
shoulder surgery. Female patients who were taking OCPs
at the time of surgery were identified, and a control group
consisting of female patients who were not taking OCPs
was formed. These groups were propensity matched in a
1:1 fashion based on age, alcohol use, and comorbidities
known to be associated with an increased risk of postoper-
ative vascular thrombosis (obesity [body mass index 30
kg/m2], diabetes, hypertension, hyperlipidemia, and smok-
ing).7 After matching, both groups were compared by the
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Charlson Comorbidity Index (CCI) to ensure adequate
matching.
The overall rate of diagnosed, symptomatic vascular
thrombosis (number of patients with upper extremity DVT,
lower extremity DVT, or PE) as well as individual rates of
upper and lower extremity DVT and PE was assessed for
patients taking OCPs and the control group within 90 days
of arthroscopic shoulder surgery.5 Vascular thrombosis was
identified by ICD-9 and ICD-10 diagnosis codes for upper
extremity DVT, lower extremity DVT, or PE. Patients who
underwent vascular ultrasound within 90 days of the index
procedure were also identified using CPT codes (93971,
93970, 93930, 93931, 93926, 93925). It should be noted that
the indication for vascular ultrasound was unidentifiable
within the database. It is possible that vascular ultrasound
was performed for a reason unrelated to developing VTE
secondary to arthroscopic shoulder surgery.
Statistical analysis was performed with Excel (Micro-
soft). Odds ratios (ORs) and 95% CIs of developing postop-
erative vascular complications were calculated with respect
to the control group. Statistical comparisons of group demo-
graphics and rates of vascular thrombosis were performed
using chi-square analysis. A Student t test was used to
compare the CCI. Risk factors for DVT were assessed using
multivariate binomial logistic regression analysis control-
ling for patient demographics and comorbidities, such as
age, sex, obesity, diabetes, and smoking status using R Stu-
dio software version 1.0.143 (R Foundation for Statistical
Computing). Matching for the control and OCP groups was
also performed with R Studio software version 1.0.143. For
all statistical comparisons, P < .05 was considered statisti-
cally significant.
RESULTS
A total of 57,727 patients underwent arthroscopic shoulder
surgery from 2007 to 2016, of whom 26,365 patients (45.7%)
were female. A total of 328 cases of vascular thrombosis
(0.57%) occurred after arthroscopic shoulder surgery,
which included 196 cases (0.34%) of PE. The rate of vascu-
lar thrombosis was not significantly different in male and
female patients (n ¼ 178 [0.57%] vs 150 [0.57%], respec-
tively; P > .99). At the time of surgery, 924 female patients
(3.5%) were taking OCPs. There was no difference in the
incidence of vascular thrombosis in patients taking OCPs
at the time of surgery versus female patients not taking
OCPs (n ¼ 2 [0.22%] vs 150 [0.57%], respectively; P ¼ .2) .
Patient age and comorbidities significantly differed in
patients taking versus not taking OCPs (P < .001) (Table
1). After a 1:1 propensity match, there were 890 patients
who were taking OCPs and 890 patients in the control
group. There were no statistical differences between
either group with respect to the age distribution and comor-
bidities (Table 1). Before matching, there was a statistical
difference in the CCI between the OCP and control groups
(0.5 vs 1.5, respectively; P < .001); however, after matching,
there was no difference in the CCI (0.5 vs 0.6, respectively; P
¼ .1).
On multivariate regression, obesity (OR, 1.43 [95% CI,
1.14-1.64]; P ¼ .002) and hypertension (OR, 2.00 [95% CI,
1.57-2.28]; P < .001) were independent risk factors for
vascular thrombosis among all female patients undergoing
arthroscopic shoulder surgery (Table 2). However, diabetes
(P ¼ .08), smoking (P ¼ .52), alcohol use (P ¼ .42),
TABLE 1
Demographic Variablesa
Variable
Unmatched Matched
OCP Control P Value OCP Control P Value
Total 924 26,365 890 890
Age, y <.001 .4
<20 116 204 108 108
20-40 358 705 325 323
41-60 434 7468 423 422
>60 16 17,988 34 37
Obesity 202 9388 <.001 185 185 >.99
Diabetes mellitus 118 8827 <.001 106 106 >.99
Hypertension 274 19,715 <.001 265 265 >.99
Hyperlipidemia 317 19,989 <.001 302 302 >.99
Smoking 90 4291 <.001 82 82 >.99
Charlson Comorbidity Index, mean 0.5 ± 1.1 1.5 ± 2.1 <.001 0.5 ± 1.1 0.6 ± 1.4 .1
aData are shown as No. unless otherwise indicated. OCP, oral contraceptive pill.
TABLE 2
Independent Risk Factors for Vascular Thrombosisa
Variable Odds Ratio (95% CI) P Value
Hypertension 2.00 (1.57-2.28) <.001
Obesity 1.43 (1.14-1.64) .002
Diabetes 1.23 (0.98-1.55) .08
Contraceptive use 0.52 (0.15-0.78) .22
Alcohol use 1.36 (0.87-2.10) .42
Hyperlipidemia 1.16 (1.01-1.33) .43
Smoking 1.10 (0.82-1.30) .52
aBolded values indicate statistical significance (P <.05).
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hyperlipidemia (P ¼ .43), age (P > .99), and OCP use (P ¼
.22) were not risk factors for vascular thrombosis. After the
1:1 propensity match, there was no statistical difference in
the total number of vascular thrombosis cases within 90
days of the index procedure in female patients who took
OCPs versus the control group (n ¼ 2 [0.22%] vs 5
[0.56%], respectively; P ¼ .2). There were no cases of upper
extremity DVT in the study population. Within each type of
arthroscopic shoulder procedure, there was no statistical
difference in the rate of developing overall vascular throm-
bosis, lower extremity DVT, or PE (P > .05) (Table 3). After
operative management, 17 patients (1.9%) who were taking
OCPs underwent vascular ultrasound within 90 days of
surgery, while 23 control patients (2.6%) underwent vascu-
lar ultrasound during the same time period (P ¼ .3). Of
these, a single patient taking OCPs (5.9%) and 3 control
patients (13.0%) were subsequently diagnosed with vascu-
lar thrombosis after ultrasound, respectively.
DISCUSSION
The principal finding of our study was that female patients
taking OCPs at the time of arthroscopic shoulder surgery
were not at an increased risk for a thromboembolic event in
comparison with female patients not taking OCPs. Our
data support retaining the null hypothesis. Secondary find-
ings include a low rate of symptomatic VTE regardless of
the risk factors analyzed in this study.We identified obesity
and hypertension as independent risk factors for thrombo-
embolic events. Additional medical risk factors analyzed in
this study were not independent risk factors for VTE.
The risk of VTE after shoulder surgery is low, with rates
quoted between 0% and 5.7%6,15,25; for arthroscopic shoul-
der surgery, the rates of symptomatic VTE are extremely
low, ranging from 0.01% to 0.38%.3,6,11,15,20,25 In this inves-
tigation, the rate of VTE after arthroscopic shoulder sur-
gery (0.57%) was higher than what has been previously
reported. OCP use is widespread and relevant to the
patient population that may undergo arthroscopic shoulder
surgery.10,23 According to data collected from the multicen-
ter RECOS Registry, OCP use was not an independent risk
factor for developing VTE after shoulder surgery (including
arthroplasty and other open procedures); however, their
total study population was 1366 patients, with only 17
patients taking OCPs at the time of surgery.10 While our
findings are in agreement with those of Imberti et al,10 our
study is more appropriately powered to detect a difference
and further supports the conclusion that OCPs do not
increase the DVT risk. A lack of association between VTE
and OCPs in arthroscopic shoulder surgery is in agreement
with more recent data regarding simple arthroscopic knee
surgery, which did not find the use of OCPs and hormone
replacement therapy to be significant independent predic-
tors of VTE after arthroscopic knee surgery.14 OCP use
appears to carry no additional risk for VTE in orthopaedic
arthroscopic surgery.
While OCPs were not associated with an increased risk
for VTE, our study did identify that obesity and hyperten-
sion were increased risk factors for the development of VTE
in female patients. Hypertension and obesity are known
risk factors for thrombus formation.18 These risk factors
may promote venous stasis and endothelial damage, which
may lead to clot formation. Schick et al20 analyzed more
than 15,000 shoulder arthroscopic procedures performed
in the United States from 2002 to 2011, and no statistically
significant risk factors were identified in the 22 cases of
reported VTE. A larger systematic review of more than
92,000 patients identified that diabetes mellitus, rheuma-
toid arthritis, and ischemic heart disease were all risk fac-
tors for developing DVT.6 Jameson et al11 found a similar
risk associated with diabetes, an increased CCI, and ische-
mic heart disease. We did not find an association with
ischemic heart disease in our group of female patients; how-
ever, the mean age was lower in our analysis, which may
have influenced the results. Medication use, such as OCPs,
was not evaluated in the prior analyses.
While the incidence of symptomatic VTE after arthro-
scopic shoulder surgery is low, a prospective evaluation of
asymptomatic VTE reported an incidence of 5.7% in 175
patients who underwent arthroscopic shoulder surgery in
the beach-chair position.25 The authors highlighted that
DVT was found 1 to 2 days postoperatively by ultrasound,
despite the use of intraoperative mechanical prophylaxis
(in the form of sequential compression devices). Only 1
patient in this study became transiently symptomatic,
which is congruent not only with the rate identified in the
present study but also consistent with the previously
reported range of 0.01% to 0.38%.11,15,25 The benefits of
chemical prophylaxis for VTE in arthroscopic shoulder sur-
gery are not clear, despite the reported findings of asymp-
tomatic VTE. A clear consensus statement on VTE
prophylaxis in arthroscopic shoulder surgery has not been
issued.10 Our findings suggest patients taking OCPs are at
no increased risk for VTE and should be treated with the
surgeon’s standard prophylaxis protocol.
The present study has several important limitations. The
data are extracted from a large private-payer database and
do not account for all surgical procedures performed in the
United States during the study period; despite this limita-
tion, the study group is a large sample size, which is useful
for detecting small differences. Because this investigation
utilizes a large private-payer database, it is subject to selec-
tion bias, as high-risk groups may be excluded from this
study. Insurance status may be an indirect indication of
higher social or financial status, which may portend better
outcomes and fewer complications. The results of this
TABLE 3
Statistical Comparisons (P Values) of
Vascular Complications by Procedurea
Complication
Labral
Repair
SLAP
Repair
Rotator
Cuff Repair
Glenohumeral
Debridement
Pulmonary
embolism
.3 — — .3
Deep vein
thrombosis
— .3 .6 .3
aSLAP, superior labral tear from anterior to posterior.
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investigation are dependent on accurate coding on behalf of
the physicians and their practices. The incidence of inaccu-
rate coding has not been assessed in this database. The
large sample also includes a large number of surgeons with
regional variations in patient selection and surgical prac-
tices, which helps support a broader application of the
study’s conclusions. There is also variation in the practice
of VTE prophylaxis, which may affect the incidence of VTE.
The results of this investigation are also reliant on how
vigorously physicians screen for VTE. The true rate of VTE
may be higher, as it is difficult to quantify the rate of
asymptomatic VTE. Pharmacy insurance claims were used
to determine which patients were prescribed OCPs, which
are more reliable than self-reported OCP use and an audit
of electronic prescriptions (which may not be filled); despite
the advantage of identifying paid prescriptions filled, we
operated under the assumption that patients who paid for
OCPs were actually taking them as prescribed at the time
of surgery. One additional limitation is that we did not
examine the use of intrauterine devices for contraceptive
use. While these devices are popular, they are not reported
to be associated with an increased risk for DVT because
they act through a different mechanism. It is possible that
the type of OCP may influence the development of VTE;
however, this variable was not assessed in the current
investigation. Previous reports did not find an association
with oral contraceptive and DVT.24
Patients with a history of DVT or PE were excluded from
the analysis. These patients were previously identified to
have an increased risk of developing a thrombolic event
after both arthroscopic shoulder and knee procedures.14
Lateral positioning, use of mechanical prophylaxis, and
operative time are factors that have been previously shown
to influence the rate of VTE development; however, these
factors were unable to be assessed and controlled for in this
investigation.12 Furthermore, the findings may be limited
because of the possibility that this investigation may be
underpowered to identify statistical differences.
CONCLUSION
OCP use at the time of arthroscopic shoulder surgery is not
associated with an increased risk of VTE. Obesity and
hypertension are associated with a greater risk for throm-
bolic events in female patients, although the risk remains
very low. Our findings suggest that patients taking OCPs
should be managed according to the surgeon’s standard
prophylaxis protocol for arthroscopic shoulder surgery.
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